Wire · operational-macro
Keytruda biosimilars are coming — but they face an uphill battle
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 2 November 2026 · Fusion42 review
Biosimilars for Merck’s Keytruda are approaching as the patent expires, but regulatory, market access, and payer challenges may limit their adoption and impact on market share.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
Keytruda biosimilars face stiff resistance from existing market controls and payer strategies, so you need to rethink access paths and pricing now to compete effectively in oncology drugs.
◆ Coverage
2 sources · 2 Nov 2026
◆ Related on Wire
◆ Topics
Biotechbiosimilarskeytrudapatent-expirymarket-accessregulation